The post Clear break above 0.5920 seems unlikely – UOB Group appeared on BitcoinEthereumNews.com. There is scope for New Zealand Dollar (NZD) to continue to edge higher; a clear break above 0.5920 seems unlikely. In the longer run, the likelihood of NZD breaking above the top of the 0.5820/0.5920 range is increasing, UOB Group’s FX analysts Quek Ser Leang and Peter Chia note. NZD may break above the top of the 0.5820/0.5920 range 24-HOUR VIEW: “We expected NZD to rise last Friday. Yesterday, when NZD was at 0.5895, we indicated that ‘there is scope for NZD to continue to edge higher, but a break above 0.5920 seems unlikely.’ Support levels are at 0.5885 and 0.5875.” 1-3 WEEKS VIEW: “After expecting NZD to trade in a 0.5820/0.5920 range since early last week, we pointed out on Friday (29 Aug, spot at 0.5880) that ‘shorter-term upward momentum has increased somewhat.’ We also pointed out that ‘the likelihood of NZD breaking above 0.5920 has also increased, and it will increase further in the coming days provided that NZD holds above 0.5835.’ We continue to hold the same view, but we are revising the ‘strong support’ level to 0.5855 from 0.5835.” Source: https://www.fxstreet.com/news/nzd-usd-clear-break-above-05920-seems-unlikely-uob-group-202509011201The post Clear break above 0.5920 seems unlikely – UOB Group appeared on BitcoinEthereumNews.com. There is scope for New Zealand Dollar (NZD) to continue to edge higher; a clear break above 0.5920 seems unlikely. In the longer run, the likelihood of NZD breaking above the top of the 0.5820/0.5920 range is increasing, UOB Group’s FX analysts Quek Ser Leang and Peter Chia note. NZD may break above the top of the 0.5820/0.5920 range 24-HOUR VIEW: “We expected NZD to rise last Friday. Yesterday, when NZD was at 0.5895, we indicated that ‘there is scope for NZD to continue to edge higher, but a break above 0.5920 seems unlikely.’ Support levels are at 0.5885 and 0.5875.” 1-3 WEEKS VIEW: “After expecting NZD to trade in a 0.5820/0.5920 range since early last week, we pointed out on Friday (29 Aug, spot at 0.5880) that ‘shorter-term upward momentum has increased somewhat.’ We also pointed out that ‘the likelihood of NZD breaking above 0.5920 has also increased, and it will increase further in the coming days provided that NZD holds above 0.5835.’ We continue to hold the same view, but we are revising the ‘strong support’ level to 0.5855 from 0.5835.” Source: https://www.fxstreet.com/news/nzd-usd-clear-break-above-05920-seems-unlikely-uob-group-202509011201

Clear break above 0.5920 seems unlikely – UOB Group

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

There is scope for New Zealand Dollar (NZD) to continue to edge higher; a clear break above 0.5920 seems unlikely. In the longer run, the likelihood of NZD breaking above the top of the 0.5820/0.5920 range is increasing, UOB Group’s FX analysts Quek Ser Leang and Peter Chia note.

NZD may break above the top of the 0.5820/0.5920 range

24-HOUR VIEW: “We expected NZD to rise last Friday. Yesterday, when NZD was at 0.5895, we indicated that ‘there is scope for NZD to continue to edge higher, but a break above 0.5920 seems unlikely.’ Support levels are at 0.5885 and 0.5875.”

1-3 WEEKS VIEW: “After expecting NZD to trade in a 0.5820/0.5920 range since early last week, we pointed out on Friday (29 Aug, spot at 0.5880) that ‘shorter-term upward momentum has increased somewhat.’ We also pointed out that ‘the likelihood of NZD breaking above 0.5920 has also increased, and it will increase further in the coming days provided that NZD holds above 0.5835.’ We continue to hold the same view, but we are revising the ‘strong support’ level to 0.5855 from 0.5835.”

Source: https://www.fxstreet.com/news/nzd-usd-clear-break-above-05920-seems-unlikely-uob-group-202509011201

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09